3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Ovarian Neoplasms
2
mCRPC
1
Prostatic Neoplasms
1
Fallopian Tube Neoplasms
1
Breast Neoplasms
1
Interventions
talazoparib
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
mCRPC
×
talazoparib
×
Clear all
NCT03395197
2026-04-22
TALAPRO-2
Pfizer
Phase 3
Active not recruiting
1,054 enrolled
21 charts
1 FDA